
|
York, 13 May 2013
Tissue Regenix Group plc ("Tissue Regenix" or "the Group"), the regenerative medical devices company which uses animal or human tissue to replace damaged or worn out parts of the human body, today announces its unaudited preliminary results for the year ended 31 January 2013.
Operational Highlights During the year, Tissue Regenix has: · Completed a successful pre-clinical study for dCELL® meniscus · Established its US subsidiary in order to target its growing regenerative medicine market · Added patents related to 'Acellular Arteries' to global exclusive licence portfolio · Produced positive interim clinical data for its dCELL® Dermis technology · Demonstrated a strong safety profile and effectiveness of its vascular patch in results from two year clinical study · Made a number... Read more from this release |
|
|
|
|
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
|
|


















